Drug discovery and development targeting the life cycle of SARS-CoV-2

A newly emerged coronavirus,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),belongs to the/β-coronavirus family and shows high similarities with SARS-CoV.O n March 11,2020,the World Health Organization(WHO)declared SARS-CoV-2 a global pandemic,and the disease was named the coronavirus disease 2019(COVID-19).The ongoing COVID-19 pandemic has caused over 46 million infections and over one million deaths worldwide,and the numbers are still increasing.Efficacious antiviral agents are urgently needed to combat this virus.The life cycle of SARS-CoV-2 mainly includes the viral attachment,membrane fusion,genomic replication,assembly and budding of virions.Accordingly,drug development against SARS-CoV-2 currently focuses on blocking spike protein binding to ACE2,inhibiting viral membrane fusion with host cells,and preventing the viral replication by targeting 3C-Iike protease,papain-like protease,RNA-dependent R N A polymerase as well as some host-cell proteins.In this review,the advances of drug development in these three major areas are elaborated.